XML 22 R11.htm IDEA: XBRL DOCUMENT v2.3.0.15
Segment Data
6 Months Ended
Sep. 30, 2011
Segment Data 
Segment Data

7.              Segment Data

 

The Company adopted ASC 280, Disclosures about Segments of an Enterprise and Related Information. ASC 280 designates the internal reporting that is used by management for making operating decisions and assessing performance as the source of the Company’s reportable segments. ASC 280 also requires disclosure about products and sources, geographic areas and major customers. The Company aggregates its product lines as two reportable segments based on the similar characteristics and markets of our products.

 

Revenues related to operations in the U.S. and foreign countries for the three and six month periods ended September 30, 2011 and 2010 are presented below. Revenues from external customers are attributed to individual countries based upon locations to which the product is shipped or exported. Net revenues from unaffiliated customers and long-lived assets related to continuing operations in the U.S. and foreign countries as of September 30, 2011 and 2010 are as follows:

 

 

 

Quarter Ended September 30

 

Six Months Ended September 30

 

(Dollars in thousands)

 

2011

 

2010

 

2011

 

2010

 

Net revenues from unaffiliated customers:

 

 

 

 

 

 

 

 

 

United States

 

$

5,811

 

$

4,701

 

$

11,303

 

$

9,609

 

Foreign (no country exceeds 10% of total)

 

3,480

 

3,053

 

6,875

 

5,600

 

 

 

$

9,291

 

$

7,754

 

$

18,178

 

$

15,209

 

 

 

 

Sept 30, 2011

 

Sept 30, 2010

 

 

 

 

 

Long-lived assets at end of quarter:

 

 

 

 

 

 

 

 

 

United States

 

$

33,083

 

$

27,874

 

 

 

 

 

 

The following table summarizes total sales by product for the three and six month periods ended September 30:

 

 

 

Three Months Ended September 30

 

Six Months Ended September 30

 

(Dollars in thousands)

 

2011

 

2010

 

2011

 

2010

 

 

 

 

 

 

 

 

 

 

 

Instrumentation Products

 

$

4,215

 

$

3,857

 

$

8,554

 

$

7,857

 

Biological Indicators

 

5,076

 

3,897

 

9,624

 

7,352

 

Total Sales

 

$

9,291

 

$

7,754

 

$

18,178

 

$

15,209

 

 

Following is the Company’s additional business segment information for September 30, 2011 and 2010:

 

(Dollars in thousands)

 

Biological 
Indicators

 

Instrumentation 
Products

 

Total

 

Quarter Ended Sept 30, 2011

 

 

 

 

 

 

 

Revenue

 

$

5,076

 

$

4,215

 

$

9,291

 

Operating Income

 

$

1,655

 

$

1,631

 

$

3,286

 

Other (Income) and Expense

 

$

52

 

$

(2

)

$

50

 

Total Assets

 

$

32,627

 

$

17,904

 

$

50,531

 

Capital Expenditures

 

$

119

 

$

63

 

$

182

 

Depreciation

 

$

120

 

$

65

 

$

185

 

Amortization

 

$

341

 

$

35

 

$

376

 

 

 

 

 

 

 

 

 

Quarter Ended Sept 30, 2010

 

 

 

 

 

 

 

Revenue

 

$

3,897

 

$

3,857

 

$

7,754

 

Operating Income

 

$

1,113

 

$

1,210

 

$

2,323

 

Other (Income) and Expense

 

$

37

 

$

(3

)

$

33

 

Total Assets

 

$

25,921

 

$

17,233

 

$

43,154

 

Capital Expenditures

 

$

60

 

$

54

 

$

114

 

Depreciation

 

$

112

 

$

43

 

$

155

 

Amortization

 

$

227

 

$

35

 

$

262

 

 

 

 

 

 

 

 

 

Six Months Ended Sept 30, 2011

 

 

 

 

 

 

 

Revenue

 

$

9,624

 

$

8,554

 

$

18,178

 

Operating Income

 

$

2,596

 

$

3,383

 

$

5,979

 

Other (Income) and Expense

 

$

105

 

$

(6

)

$

99

 

Total Assets

 

$

32,627

 

$

17,904

 

$

50,531

 

Capital Expenditures

 

$

213

 

$

130

 

$

343

 

Depreciation

 

$

245

 

$

105

 

$

350

 

Amortization

 

$

672

 

$

80

 

$

752

 

 

 

 

 

 

 

 

 

Six Months Ended Sept 30, 2010

 

 

 

 

 

 

 

Revenue

 

$

7,352

 

$

7,857

 

$

15,209

 

Operating Income

 

$

1,830

 

$

2,707

 

$

4,537

 

Other (Income) and Expense

 

$

52

 

$

(6

)

$

46

 

Total Assets

 

$

25,921

 

$

17,233

 

$

43,154

 

Capital Expenditures

 

$

2,326

 

$

134

 

$

2,460

 

Depreciation

 

$

224

 

$

98

 

$

322

 

Amortization

 

$

432

 

$

80

 

$

512